EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A neutralizing single-domain antibody that targets the trimer interface of the human metapneumovirus fusion protein

Marlies Ballegeer, Revina C van Scherpenzeel, Teresa Delgado, Maria Iglesias-Caballero, Blanca García Barreno, Shubham Pandey, Scott A Rush, Joost A Kolkman, Vicente Mas iD, Jason S McLellan iD, Xavier Saelens iD

mBio · 16.01.2024 · 15 (1)

DOI: 10.1128/mbio.02122-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, erschienen am 16.01.2024. Verfasst von Marlies Ballegeer und 10 weiteren Autor:innen. Beteiligte Einrichtung: VIB Center for Medical Biotechnology, VIB, Ghent, Belgium. Hauptthemen laut MEDLINE: Metapneumovirus, Single-Domain Antibodies. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Auris | J&J | Janssen Pharmaceuticals (Janssen Pharmaceuticals, Inc.), Welch Foundation (The Welch Foundation), NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human metapneumovirus (hMPV) is a leading cause of viral lower respiratory tract disease in children and adults. The hMPV fusion protein F is a trimeric class I fusion protein that is initially synthesized as a precursor (F 0 ) and requires proteolytic activation by a host cell protease to generate the metastable, fusion-competent prefusion conformation of F. hMPV F is considered the main target of the neutralizing antibody response against hMPV infection. We isolated single-domain antibodies (sdAbs) directed against hMPV F that potently neutralize hMPV A and B strains. One of these sdAbs, sdHMPV16, specifically bound to cleaved and uncleaved prefusion F. Co-crystal structure analysis revealed that sdHMPV16 binds to a site located at the trimer interface of prefusion F. Moreover, prophylactic treatment with a sdHMPV16-Fc fusion protein reduced viral titers in the lungs of hMPV-infected cotton rats. In summary, sdHMPV16 broadly neutralizes hMPV, can be turned into a candidate biologic that restricts hMPV replication in an in vivo model, and, unexpectedly, binds to an unconventional epitope at the prefusion F trimer interface. IMPORTANCE Human metapneumovirus (hMPV) is an important respiratory pathogen for which no licensed antivirals or vaccines exist. Single-domain antibodies represent promising antiviral biologics that can be easily produced and formatted. We describe the isolation and detailed characterization of two hMPV-neutralizing single-domain antibodies that are directed against the fusion protein F. One of these single-domain antibodies broadly neutralizes hMPV A and B strains, can prevent proteolytic maturation of F, and binds to an epitope in the F trimer interface. This suggests that hMPV pre-F undergoes trimer opening or “breathing” on infectious virions, exposing a vulnerable site for neutralizing antibodies. Finally, we show that this single-domain antibody, fused to a human IgG1 Fc, can protect cotton rats against hMPV replication, an important finding for potential future clinical applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetapneumovirusSingle-Domain AntibodiesHumansAntibodies, ViralAntibodies, NeutralizingEpitopesViral Fusion Proteins

Stichwörter der Autor:innen

fusion proteinhuman metapneumovirussingle-domain antibodystructure

Substanzen

Single-Domain AntibodiesAntibodies, ViralAntibodies, NeutralizingEpitopesViral Fusion Proteins

Autor:innen und Institutionen

  • VIB Center for Medical Biotechnology, VIB, Ghent, Belgium.
  • Department of Biochemistry and Microbiology, Ghent University, Ghent, Belgium.
  • Janssen Infectious Diseases and Vaccines, Beerse, Belgium.
  • Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain.
  • Department of Molecular Biosciences, The University of Texas at Austin, Austin, Texas, USA.

ORCID-Profile: Vicente Mas, Jason S McLellan, Xavier Saelens

Förderung

  • Auris | J&J | Janssen Pharmaceuticals (Janssen Pharmaceuticals, Inc.)
  • Welch Foundation (The Welch Foundation)
  • NIAID NIH HHS
  • NIGMS NIH HHS
  • NCI NIH HHS
  • NIH HHS

Zitieren

APA

Ballegeer, M., van Scherpenzeel, R. C., Delgado, T., Iglesias-Caballero, M., García Barreno, B., Pandey, S., Rush, S. A., Kolkman, J. A., Mas, V., McLellan, J. S., & Saelens, X. (2024). A neutralizing single-domain antibody that targets the trimer interface of the human metapneumovirus fusion protein. mBio, 15(1). https://doi.org/10.1128/mbio.02122-23

Vancouver

Ballegeer M, van Scherpenzeel RC, Delgado T, Iglesias-Caballero M, García Barreno B, Pandey S, et al. A neutralizing single-domain antibody that targets the trimer interface of the human metapneumovirus fusion protein. mBio. 2024;15(1). doi:10.1128/mbio.02122-23

BibTeX
@article{Ballegeer2024,
  author = {Ballegeer, Marlies and van Scherpenzeel, Revina C and Delgado, Teresa and Iglesias-Caballero, Maria and García Barreno, Blanca and Pandey, Shubham and Rush, Scott A and Kolkman, Joost A and Mas, Vicente and McLellan, Jason S and Saelens, Xavier},
  title = {A neutralizing single-domain antibody that targets the trimer interface of the human metapneumovirus fusion protein},
  journal = {mBio},
  year = {2024},
  volume = {15},
  number = {1},
  doi = {10.1128/mbio.02122-23}
}
Kostenlos starten →